MapLight Therapeutics

MPLT

Market cap $1.63B

SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company's Annual Meeting of Stockholders on June 23, 2026. Mr. Babler and Mr. Cox succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election and have concluded their service on the Board. Mr. Babler has been appointed as a member of the Audit Committee, and Mr. Cox has been appointed Chair of the Nominating and Corporate Governance Committee.

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Phase II IRIS Study Results for ML-004 in Autism Spectrum Disorder Transcript

MapLight Therapeutics Inc. (NASDAQ:MPLT) reported mixed topline results from its Phase 2 IRIS study of ML-004 in patients with autism spectrum disorder.

SAN FRANCISCO and BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder (ASD). The study randomized 161 participants (102 adolescents, 59 adults), with prespecified analyses planned by age group and baseline irritability severity.

Enrollment completed in ML-007C-MA's Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004's Phase 2 IRIS trial in autism spectrum disorder, with topline results expected by mid-August 2026 Enrollment ongoing in ML-007C-MA's Phase 2 VISTA trial in Alzheimer's disease psychosis, with topline results expected in the second half of 2027 Ended the quarter with $395.2 million in cash, cash equivalents and investments, which is expected to fund operations through 2027 SAN FRANCISCO and BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “We are continuing to see strong momentum across our clinical portfolio, including completion of enrollment in the Phase 2 ZEPHYR and IRIS trials,” said Chris Kroeger, co-Founder and Chief Executive Officer of the Company.

SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:

SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August 2026.

Needham initiated coverage on MapLight Therapeutics Inc. (NASDAQ: MPLT). The company, which is focused on central nervous system disorders, debuted on NASDAQ in October 2025 and raised $296.3 million in IPO gross proceeds.

SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences: Event: Jefferies 2026 Biotech on the Beach Summit (Miami, FL) Date: Tuesday, March 10th Format: Hosting 1x1 meetings Event: Leerink 2026 Global Healthcare Conference (Miami, FL) Date: Wednesday, March 11th Format: Presenting and hosting 1x1 meetings Event: Stifel 2026 Virtual CNS Forum Date: Wednesday, March 18th Format: Presenting and hosting 1x1 meetings Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company's website at https://ir.maplightrx.com/news-events/events-presentations. About MapLight Therapeutics MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.